Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The JAK2 46/1 haplotype influences PD-L1 expression

  • Carreño-Tarragona, Gonzalo
  • Tiana, María
  • Rouco, Raquel
  • Leivas, Alejandra
  • Victorino, Jesús
  • García-Vicente, Roberto
  • Chase, Andrew J.
  • Maidana, Andrea
  • Tapper, William J.
  • Ayala, Rosa
  • Cross, Nicholas C. P.
  • Martínez-López, Joaquín
  • Manzanares, Miguel
Although described more than a decade ago, the mechanism by which the JAK2 46/1 haplotype increases the risk of developing JAK2-mutated myeloproliferative neoplasms (MPNs) remains unexplained. Inflammation and immunity are linked to MPN development and thus could be relevant to the mechanism by which 46/1 mediates its effect. Here, we show that programmed death-1 receptor ligand (PD-L1) expression is elevated in 46/1 haplotype, both in healthy carriers and in CD34 cells from patients with MPN. Using circular chromosome conformation capture, we observed that PD-L1 and the neighboring PD-L2 loci physically interact with JAK2 in a manner that differs between 46/1 and nonrisk haplotypes. CRISPR/Cas9 genome editing identified a region within JAK2 intron 2 that influences both JAK2 and PD-L1 expression. We suggest that increased PD-L1 expression may be relevant to the mechanism by which 46/1 leads to an increased inherited risk of developing MPN., This study was funded by the Asociacion Española Contra el Cáncer (AECC) Ideas Semilla AECC 2017 grants PID2020-115755GB-I00 and PID2023-151742NB-I00 (funded by Ministerio de Ciencia, Innovacion y Universidades /Agencia Estatal de Investigación [AEI]/10.13039/ 501100011033); by the Subdireccion General de Investigación Sanitaria ´ (Instituto de Salud Carlos III, Spain) grant PI19/01518; by the Cancer Research Innovation in Science (CRIS) Against Cancer Foundation grant 2018/001; and by the Instituto de Investigacion Hospital 12 de Octubre (IMAS12). CBM is supported by an institutional grant from the Fundacion Ramón Areces and Severo Ochoa Center of Excellence (grant CEX2021-001154-S, funded by Ministerio de Ciencia e Innovacion /AEI/10.13039/501100011033).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

  • Ayala, Rosa|||0000-0002-2699-8353
  • Rapado, Inmaculada
  • Onecha, Esther
  • Martínez-Cuadrón, David|||0000-0001-7540-4091
  • Carreño-Tarragona, Gonzalo|||0000-0002-9570-5542
  • Bergua Burgues, Juan Miguel|||0000-0001-8229-1208
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Algarra Algarra, Jesus Lorenzo
  • Tormo, Mar|||0000-0001-9622-1649
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Serrano, Josefina
  • Herrera, Pilar|||0000-0002-4118-7110
  • Ramos, Fernando
  • Salamero, Olga|||0000-0003-3237-0025
  • Lavilla, Esperanza|||0000-0003-1490-0678
  • Gil, Cristina
  • López Lorenzo, José L.|||0000-0003-1502-3902
  • Vidriales, María Belén|||0000-0001-5049-3673
  • Labrador, Jorge|||0000-0002-3696-0287
  • Falantes, José Francisco|||0000-0001-8660-7038
  • Sayas, María José
  • Paiva, Bruno|||0000-0003-1977-3815
  • Barragán, Eva
  • Prosper, Felipe|||0000-0001-6115-8790
  • Sanz, Miguel A.|||0000-0003-1489-1177
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Montesinos, Pau|||0000-0002-3275-5593
Mutational profiling using a custom 43-gene next-generation sequencing panel revealed that patients with mutated DNMT3A or EZH2, or an increase in TET2 VAF and lower TP53 VAF showed a higher overall response. NRAS and TP53 variants were associated with shorter overall survival (OS), whereas only mutated BCOR was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low-intermediate cytogenetic risk and mutated NRAS benefited from azacytidine therapy and patients with mutated TP53 showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. We sought to predict treatment responses and outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status, comparing azacytidine (AZA) with fludarabine plus low-dose cytarabine (FLUGA). Mutational profiling using a custom 43-gene next-generation sequencing panel revealed differences in profiles between older and younger patients, and several prognostic markers that were useful in young patients were ineffective in older patients. We examined the associations between variables and overall responses at the end of the third cycle. Patients with mutated DNMT3A or EZH2 were shown to benefit from azacytidine in the treatment-adjusted subgroup analysis. An analysis of the associations with tumor burden using variant allele frequency (VAF) quantification showed that a higher overall response was associated with an increase in TET2 VAF (odds ratio (OR), 1.014; p = 0.030) and lower TP53 VAF (OR, 0.981; p = 0.003). In the treatment-adjusted multivariate survival analyses, only the NRAS (hazard ratio (HR), 1.9, p = 0.005) and TP53 (HR, 2.6, p = 9.8 × 10 -7) variants were associated with shorter overall survival (OS), whereas only mutated BCOR (HR, 3.6, p = 0.0003) was associated with a shorter relapse-free survival (RFS). Subgroup analyses of OS according to biological and genomic characteristics showed that patients with low-intermediate cytogenetic risk (HR, 1.51, p = 0.045) and mutated NRAS (HR, 3.66, p = 0.047) benefited from azacytidine therapy. In the subgroup analyses, patients with mutated TP53 (HR, 4.71, p = 0.009) showed a better RFS in the azacytidine arm. In conclusion, differential mutational profiling might anticipate the outcomes of first-line treatment choices (AZA or FLUGA) in older patients with AML. The study is registered at ClinicalTrials.gov as NCT02319135.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Impact of FLT3-ITD mutation status and its ratio in a cohort of 2901 patients undergoing upfront intensive chemotherapy: a PETHEMA registry study

  • Ayala, Rosa
  • Carreño-Tarragona, Gonzalo
  • Barragán, Eva
  • Boluda, Blanca
  • Larráyoz, María José
  • Chillón, María Carmen
  • Carrillo-Cruz, Estrella
  • Bilbao, Cristina
  • Sánchez-García, Joaquín
  • Bernal del Castillo, Teresa
  • Martínez-Cuadrón, David
  • Gil, Cristina
  • Serrano, Josefina
  • Rodríguez-Medina, Carlos
  • Bergua, Juan
  • Pérez-Simón, José A.
  • Calbacho, María
  • Alonso-Domínguez, Juan M.
  • Labrador, Jorge
  • Tormo, Mar
  • Amigo, María Luz
  • Herrera-Puente, Pilar
  • Rapado, Inmaculada
  • Sargas, Claudia
  • Vázquez Urio, Iria
  • Calasanz, María José
  • Gómez-Casares, Teresa
  • García-Sanz, Ramón
  • Sanz, Miguel A.
  • Martínez-López, Joaquín
  • Montesinos, Pau
FLT3-ITD results in a poor prognosis in terms of overall survival (OS) and relapse-free survival (RFS) in acute myeloid leukemia (AML). However, the prognostic usefulness of the allelic ratio (AR) to select post-remission therapy remains controversial. Our study focuses on the prognostic impact of FLT3-ITD and its ratio in a series of 2901 adult patients treated intensively in the pre-FLT3 inhibitor era and reported in the PETHEMA registry. A total of 579 of these patients (20%) harbored FLT3-ITD mutations. In multivariate analyses, patients with an FLT3-ITD allele ratio (AR) of >0.5 showed a lower complete remission (CR rate) and OS (HR 1.47, p = 0.009), while AR > 0.8 was associated with poorer RFS (HR 2.1; p < 0.001). Among NPM1/FLT3-ITD-mutated patients, median OS gradually decreased according to FLT3-ITD status and ratio (34.3 months FLT3-ITD-negative, 25.3 months up to 0.25, 14.5 months up to 0.5, and 10 months ≥ 0.5, p < 0.001). Post-remission allogeneic transplant (allo-HSCT) resulted in better OS and RFS as compared to auto-HSCT in NPM1/FLT3-ITD-mutated AML regardless of pre-established AR cutoff (≤0.5 vs. >0.5). Using the maximally selected log-rank statistics, we established an optimal cutoff of FLT3-ITD AR of 0.44 for OS, and 0.8 for RFS. We analyzed the OS and RFS according to FLT3-ITD status in all patients, and we found that the group of FLT3-ITD-positive patients with AR < 0.44 had similar 5-year OS after allo-HSCT or auto-HSCT (52% and 41%, respectively, p = 0.86), but worse RFS after auto-HSCT (p = 0.01). Among patients with FLT3-ITD AR > 0.44, allo-HSCT was superior to auto-HSCT in terms of OS and RFS. This study provides more evidence for a better characterization of patients with AML harboring FLT3-ITD mutations., We thank all patients for agreeing to participate in these studies. This study was funded by Instituto de Salud Carlos III (ISCIII) through the project PI19/01518 and PI19/00730 and co-funded by the European Union, the CRIS Against Cancer Foundation, grant 2018/001, and by the Instituto de Investigación Hospital 12 de Octubre (IMAS12). A complete list of the institutions and clinicians participating in the PETHEMA epidemiologic registry of acute myeloid leukemia and acute promyelocytic leukemia appears in the Supplementary Material.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

  • Simoes, Catia
  • Chillón, María Carmen
  • Martínez-Cuadrón, David
  • Calasanz, María José
  • Vridiales, María-Belén
  • Vázquez Urio, Iria
  • Hernández-Ruano, Montserrat
  • Ariceta, Beñat
  • Aguirre-Ruiz, Paula
  • Burgos, Leire
  • Alignani, Diego
  • Sarvide, Sarai
  • Villar, Sara
  • Alfonso Pierola, Ana
  • Prósper, Felipe
  • Ayala, Rosa
  • Martínez-López, Joaquín
  • Bergua Burgués, Juan Miguel
  • Vives, Susana
  • Pérez-Simón, José A.
  • García-Fortes, María
  • Bernal del Castillo, Teresa
  • Colorado, Mercedes
  • Olave, Mayte
  • Rodríguez-Gutiérrez, Juan I.
  • Labrador, Jorge
  • Gonzalez Díaz, Marcos
  • San-Miguel, Jesús F.
  • Sanz, Miguel A.
  • Montesinos, Pau
  • Paiva, Bruno David Lourenço
Clonal evolution in acute myeloid leukemia (AML) originates long before diagnosis and is a dynamic process that may affect survival. However, it remains uninvestigated during routine diagnostic workups. We hypothesized that the mutational status of bone marrow dysplastic cells and leukemic blasts, analyzed at the onset of AML using integrated multidimensional flow cytometry (MFC) immunophenotyping and fluorescence-activated cell sorting (FACS) with next-generation sequencing (NGS), could reconstruct leukemogenesis. Dysplastic cells were detected by MFC in 285 of 348 (82%) newly diagnosed patients with AML. Presence of dysplasia according to MFC and World Health Organization criteria had no prognostic value in older adults. NGS of dysplastic cells and blasts isolated at diagnosis identified 3 evolutionary patterns: stable (n = 12 of 21), branching (n = 4 of 21), and clonal evolution (n = 5 of 21). In patients achieving complete response (CR), integrated MFC and FACS with NGS showed persistent measurable residual disease (MRD) in phenotypically normal cell types, as well as the acquisition of genetic traits associated with treatment resistance. Furthermore, whole-exome sequencing of dysplastic and leukemic cells at diagnosis and of MRD uncovered different clonal involvement in dysplastic myelo-erythropoiesis, leukemic transformation, and chemoresistance. Altogether, we showed that it is possible to reconstruct leukemogenesis in ~80% of patients with newly diagnosed AML, using techniques other than single-cell multiomics., This work was supported by grants from the Área de Oncología del Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red (CIBER-ONC) (CB16/12/00369, CB16/12/00233, CB16/12/ 00489, and CB16/12/00284), Instituto de Salud Carlos III/Sub-dirección General de Investigación Sanitaria (FIS numbers PI16/ 01661, PI16/00517, and PI19/01518), and the Plan de Investigación de la Universidad de Navarra (PIUNA 2014-18). This work was supported internationally by the Cancer Research UK, FCAECC, and AIRC under the Accelerator Award Program (EDITOR).